On February 14, 2018, the FDA approved apalutamide (Erleada) by Janssen Biotech Inc for the treatment of nonmetastatic castration-resistant prostate cancer (NM-CRPC).
Christa Eans, PharmD, AAHIVP, MSPBA
Advertisement
Articles by Christa Eans, PharmD, AAHIVP, MSPBA
Advertisement
Latest Updated Articles
ERLEADA for Prostate CancerPublished: September 4th 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
2
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
3
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5
